Evaluating a new bypass conduit for patients with peripheral artery disease
Prospective, Non-randomized, Early Feasibility Clinical Study to Assess the Feasibility of the Novel Xeltis Peripheral Artery Disease (XPAD) Bypass Conduit
This study is testing a new bypass conduit to see if it can safely help people with peripheral artery disease who need surgery on their legs.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 6 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Xeltis Industry-sponsored |
| Locations | 1 site (San José) |
| Trial ID | NCT06951685 on ClinicalTrials.gov |
What this trial studies
This study aims to assess the safety and performance of the Xeltis Peripheral Artery Disease (XPAD) Bypass Conduit in patients suffering from peripheral artery occlusive disease (PAOD) who are scheduled for elective above-knee femoral popliteal bypass surgery. It is a prospective, single-arm, non-randomized early feasibility study that will involve monitoring patients before and after the procedure. The study will include patients with specific Rutherford grades of vascular disease and suitable anatomical conditions as determined by imaging studies.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with femoral artery occlusion requiring elective above-knee femoral popliteal bypass surgery and specific Rutherford grades of occlusive vascular disease.
Not a fit: Patients requiring cardiac surgical procedures or other vascular surgeries may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new treatment option that improves outcomes for patients with peripheral artery disease undergoing bypass surgery.
How similar studies have performed: While this approach is novel, similar studies evaluating new vascular conduits have shown promise in improving surgical outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Subjects with femoral artery occlusion who require elective above-knee femoral popliteal bypass surgery 2. Patient has Rutherford grade 3, 4, or 5 occlusive vascular disease and TASC C or D lesions. Rutherford grade 5 may be included with a wound, ischemia and foot infection (WiFi) classification of up to grade 2, provided there are two outflow vessels with at least one reaching the pedal arch 3. At least 18 years of age at screening 4. Suitable anatomy (assessed by a pre-procedural contrasted CT scan or previous angiogram assessed up to 90 days prior to baseline) 5. Patient has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent 6. Patient has been informed and agrees to pre- and post-procedure follow-up, including follow-up angiography 7. Life expectancy of at least 24 months Exclusion Criteria: 1. Subject requires, or is scheduled for, a cardiac surgical procedure or a different vascular surgical procedure within 30 days of study procedure. 2. Presence or history of bypass in the diseased limb 3. Subject requires sequential extremity revascularizations or other procedures that require use of additional vascular grafts 4. Stroke or myocardial infarction event within 6 weeks of the procedure or evidence of prior massive stroke (Modified Rankin Scale 3 or above) 5. History of acute arterial occlusion requiring an emergent intervention 6. Severe chronic renal insufficiency (serum creatinine \>2.5 mg/dL) or undergoing hemodialysis 7. Previous renal transplant 8. Uncontrolled arterial hypertension (BP \>200 mmHg) at 2 successive readings 9. Uncontrolled or poorly controlled diabetes 10. Abnormal blood values that could influence patient recovery and or/ graft hemostasis 11. Reduced liver function, defined as: \>2x the upper limit of normal for serum bilirubin, International Normalized Ratio (INR) \>1.5 or prothrombin time (PT) \>18 seconds 12. Any active local or systemic infection 13. Known heparin-induced thrombocytopenia 14. Known active bleeding disorder and/or any coagulopathy or thromboembolic disease 15. Allergies to study device (nitinol) or agents/medication, such as contrast agents or aspirin, that can't be controlled medically 16. Previous enrolment in this study 17. Subject is participating in another study 18. Pregnant or breastfeeding woman or woman in fertile period not taking adequate contraceptives 19. Any other condition which, in the judgement of the investigator would preclude adequate evaluation for the safety and performance of the study conduit Intra-operative exclusion criteria: 1\. Unsuitable anatomy to implant the XPAD conduit (e.g. target vessel diameter smaller than anticipated; severe calcification)
Where this trial is running
San José
- Centro de Investigación y Manejo del Cáncer (CIMCA) — San José, Costa Rica (Recruiting)
Study contacts
- Study coordinator: Methee Schreuder
- Email: clinical@xeltis.com
- Phone: +31 40 751 7614
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.